Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

L19-tumor necrosis factor alpha (L19mTNF-α; L), a fusion protein consisting of mouse TNFα and the human antibody fragment L19 directed to the extra domain-B (ED-B) of fibronectin, is able to selectively target tumor vasculature and to exert a long-lasting therapeutic activity in combination with mel...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortara, Lorenzo, Orecchia, Paola, Castellani, Patrizia, Borsi, Laura, Carnemolla, Barbara, Balza, Enrica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799282/
https://www.ncbi.nlm.nih.gov/pubmed/24156020
http://dx.doi.org/10.1002/cam4.89

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799282/
https://www.ncbi.nlm.nih.gov/pubmed/24156020
http://dx.doi.org/10.1002/cam4.89

Ejemplares similares